Phase Ib, non-randomized, single-arm, open-label, single-center clinical trial to evaluate the safety of the first-in-human administration of the combination of dendritic cell (DC) immunization pulsed with tumor lysate and CAR-T cells targeting IL13Ra2 in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
This study is a very early investigation into a new treatment for diffuse intrinsic pontine glioma (DIPG), a type of brain tumour, in newly diagnosed young patients. It's a 'Phase Ib' trial, meaning the main goal is to carefully check if the treatment is safe for people. Researchers are testing a combination of two new approaches: a special vaccine made from the patient's own tumour, and immune cells (CAR-T cells) that have been specially trained to target the cancer. This is the first time this specific combination treatment is being given to humans. The study will closely monitor for any side effects and see how patients respond, comparing results with standard treatments used in the past. It's an important step in finding better ways to treat this challenging condition.
At a glance
What is this study about?
This groundbreaking study is looking for new ways to treat a very serious type of brain tumour called diffuse intrinsic pontine glioma, or DIPG, which usually affects children and young adults. Because DIPG is so hard to treat with current methods, researchers are constantly searching for better options. This trial is special because it's combining two advanced therapies.
First, there's a 'dendritic cell vaccine.' You can think of dendritic cells as special messengers in our immune system. In this treatment, these cells are taken from the patient, trained in the lab using parts of their own tumour, and then given back to the patient. The idea is to teach the body's immune system to recognise and attack the cancer cells. The second part of the treatment involves 'CAR-T cells.' These are the patient's own immune cells that are modified in the lab to specifically find and destroy DIPG cells.
This particular study is a 'first-in-human' trial, meaning it's the very first time this exact combination of treatments is being given to people. Because it's so new, the main goal is to make sure it's safe. Doctors will be watching very closely for any side effects. They will also start to gather information on how well the treatment works, how it affects the tumour, and the overall health and quality of life of the patients involved. This early step is crucial for developing potentially life-saving treatments in the future.
Key takeaways
- This is an early-stage study checking the safety of a new combination treatment for DIPG.
- It uses a special vaccine and modified immune cells (CAR-T cells).
- The main goal is to carefully watch for any side effects.
- It's the first time this specific combination is being given to humans.
- The study also aims to gather initial information on how the treatment affects the tumour and quality of life.
Who may be eligible?
To be considered for this study, you need to be a young person or adult, aged 18 or older, who has recently been diagnosed with diffuse intrinsic pontine glioma (DIPG).
Because this is a very specific early-stage study, there are other rules about your overall health, any other medical conditions you might have, and previous treatments you may have received. These rules are in place to make sure the study is safe for you and that the results are as clear as possible.
You should discuss with your doctor if this study might be suitable for you, as they will be able to check all the detailed requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or over?
- Have you recently been diagnosed with DIPG?
- Are you able to travel to the study centre for appointments?
- Do you have a general good health status apart from your DIPG?
- Are you willing to undergo various tests like blood draws and scans?
What does participation involve?
If you decide to take part in this study, you will receive a combination of treatments. The study involves a special vaccine (DIPG-DC) and modified immune cells (ARI0008, a type of CAR-T cell). You will have regular visits to the hospital for these treatments, and to have various tests such as blood samples, scans, and possibly samples of the fluid around your brain and spinal cord (CSF).
Doctors will carefully monitor your health throughout the study for any changes or side effects. There will be detailed checks on how your immune system is responding and how the tumour is behaving. You may also be asked to complete questionnaires about your quality of life. The exact duration of your participation in the treatment phase will depend on your individual response, but there will be ongoing follow-up after the main treatment is completed to monitor your long-term health and the effects of the treatment.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is a 'Phase Ib' study?
This is a very early stage of research where doctors mainly check if a new treatment is safe for people, and start to look for the right dose, before testing how well it works on a larger scale.
What is DIPG?
DIPG (Diffuse Intrinsic Pontine Glioma) is a serious and aggressive type of brain tumour that grows in a part of the brainstem called the pons, which controls many vital body functions.
What are CAR-T cells?
CAR-T cells are your own immune cells that have been specially trained in the lab to recognise and attack cancer cells, like tiny guided missiles.
Will I get this new treatment or the standard treatment?
In this specific study, everyone who participates will receive the new combination treatment, as it's designed to see how the treatment works.
Will I have to travel for this study?
Yes, this study is being conducted at a single centre, so you would need to travel to that hospital for all appointments and treatments.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.